Fido's Drugmaker Slammed Despite Easy Beat On Growing Pet Sales

Fido's Drugmaker Slammed Despite Easy Beat On Growing Pet Sales

Bullish spending on pet health helped Zoetis easily beat first-quarter expectations. But Zoetis stock crumbled after the open. That put shares well below a buy point out of a consolidation.